Maturity-onset diabetes of the young (MODY) is characterized by a nonketotic form of diabetes mellitus transmitted by an autosomal dominant mode of inheritance that is usually diagnosed before the age of 25 years. *HNF4A* (MODY1), *HNF1A* (MODY3), *PDX1* (MODY4), *HNF1B* (MODY5), and *NEUROD1* (MODY6) encode transcription factors operational in the pancreatic *β*-cell, whereas *GCK* (MODY2) encodes the *β*-cell glycolytic enzyme glucokinase. Mutations in these genes cause *β*-cell dysfunction, which leads to the development of MODY ([@B1]). More recently, additional genes have been identified as rarer causes of MODY 7 through MODY 13, including *KLF11* ([@B2]), *CEL* ([@B3]), *PAX4* ([@B4]), *INS* ([@B5]), *BLK* ([@B6]), *ABCC8* ([@B7]), and *KCNJ11* ([@B8]). In contrast to MODY, type 2 diabetes is a polygenic disease and an illness of insulin resistance and relative insulinopenia.

Large candidate gene studies have identified common genetic variants in genes responsible for MODY 1 through MODY 6 that are associated with type 2 diabetes and glycemic traits ([@B9][@B10]--[@B11]). Bonnycastle *et al.* ([@B9]), in a cross-sectional study, showed that genetic variation in *GCK*, *NEUROD1*, *HNF4A*, *HNF1A*, and *HNF1B* was nominally associated (*P* \< 0.05) with diabetes risk after considering multiple testing. Winckler *et al.* ([@B10]) did not replicate these findings in their cross-sectional analyses but did show a consistent relationship between an *HNF1B* variant and diabetes risk in two independent cohorts. A prospective observational study revealed an association between *HNF1A* and *HNF4A* common genetic variation and diabetes incidence ([@B11]). A cross-sectional study showed no association between groups of 121 rare missense variants identified by sequencing seven MODY genes and early-onset diabetes in a population without particular risks for diabetes ([@B12]). A prior study found no association between *HNF4A* and oral disposition index (DI~o~) ([@B11]), and other studies have primarily examined how *GCK* variants influence insulin secretion ([@B13][@B14][@B15]--[@B16]).

Genome-wide association studies (GWASs) have further confirmed a relationship between MODY genes and diabetes risk ([@B17][@B18][@B19]--[@B20]). Genetic variants in *HNF4A* ([@B19], [@B20]), *HNF1A* ([@B17], [@B18], [@B21]), and *HNF1B* ([@B17], [@B22]) have been associated with diabetes risk in populations of European, Hispanic, South Asian, or East Asian descent at genome-wide statistical significance (*P* \< 5 × 10^--8^). GWASs have also detected associations of common variants in *GCK* with fasting glucose ([@B23][@B24]--[@B25]) and hemoglobin A1~c~ ([@B24], [@B26]).

These data show that MODY genes may influence the development of type 2 diabetes and modulate glycemic traits. In our comprehensive analysis of candidate genes in the Diabetes Prevention Program (DPP) ([@B27]), a clinical trial that evaluated preventive strategies for type 2 diabetes, we found that rs11868513 (*HNF1B*) was associated with diabetes incidence only in the placebo group, with both metformin and lifestyle interventions showing significant evidence as effect modifiers; and rs11086926 (*HNF4A*) was associated with diabetes incidence only in the metformin group, with metformin but not the lifestyle intervention showing significant evidence as an effect modifier ([@B27]). Here we build upon these findings by exploring the physiological underpinnings of this association further and investigating how common and rare missense genetic variation in MODY genes may influence insulin secretion in response to insulin-sensitizing interventions.

Methods {#s8}
=======

The DPP enrolled 3548 US participants from multiple ethnicities with high-risk criteria for diabetes development: overweight, elevated fasting glucose, and impaired glucose tolerance. Of these participants with complete clinical data and consent for genetic testing, 2806 were randomized to placebo (n = 944), metformin 850 mg twice daily (n = 927), or lifestyle intervention (n = 935) with a goal weight loss of ≥7% and ≥150 minutes of physical activity per week; a fourth troglitazone treatment arm was terminated early due to concerns for drug-related hepatotoxicity ([@B28]). Participants in this arm (n = 585) were included in genotyping and baseline association analyses, but not included in longitudinal association testing due to early termination ([@B28]). Ethical approval was obtained by local human research committees, and all participants signed informed consent forms.

We used Sanger sequencing on an ABI 3730 DNA Analyzer to sequence the exons and splice sites of the six MODY-causing genes (*HNF4A*, *GCK*, *HNF1A*, *PDX1*, *HNF1B*, and *NEUROD1*) in 190 DPP participants. Samples were chosen without regard to subsequent diabetes incidence with relatively equal distribution of males and females (44% male, 56% female) and ethnicity. Sequencing coverage across the MODY 1 through MODY 6 genes was completed in a three-step primer redesign process to maximize coverage of all MODY genes. Forty-three amplicons were designed to sequence exons 1 through 10 and the promoter region in *HNF4A*, exons 1 through 10 in *GCK* and *HNF1A*, exons 1 and 2 in *PDX1*, 9 exons in *HNF1B*, and exon 2 in *NEUROD1* (exon 1 is untranslated). An overlap of amplicons provided additional genotypes that had polymorphism concordance of 99.5% across all amplicons. The average targeted coverage was 95%.

Twenty-two missense single-nucleotide polymorphisms (SNPs) were identified by Sanger sequencing (three with minor allele frequency \[MAF\] \>5% and 19 with MAF \<5%) and subsequently genotyped in all DPP participants. DNA was whole-genome amplified with the REPLI-G (Qiagen) kit and purified using Nucleofast (Machery-Nagel). Genotyping was performed by allele-specific primer extension of multiplex amplified products, with detection by matrix-assisted laser desorption ionization--time-of-flight mass spectroscopy on an iPLEX-GOLD Sequenom platform. The genotyping success rate was 99%, and concordance rate between sequence data and Sequenom genotyping was 99.5%. We used publicly available assessment tools, PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2>) and SIFT (<http://sift.jcvi.org>), to predict whether amino acid changes could be detrimental to protein function ([@B29][@B30]--[@B31]).

We used Tagger ([@B32]) to select tagging SNPs that would capture (*r*^2^ ≥ 0.8) all variations with MAF \>1% in European (CEU) and/or African (YRI) HapMap populations in MODY genes. The 221 tag SNPs were genotyped on a custom-designed oligonucleotide pool array with other diabetes-related candidate SNPs. Further details regarding genotyping are described in Jablonski *et al.* ([@B27]).

Glucose (in milligrams per deciliter) and insulin (in units per milliliter) were measured fasting and 30 minutes after a 75-g glucose load at baseline and year 1 ([@B33]). We focused on the following two quantitative traits as measurements for insulin secretion: change in the insulinogenic index (InsIndex) and DI~o~ over the first year after randomization. Insulin secretion indices were calculated as follows: InsIndex (U/mL)/(mg/dL) = (30-minute insulin -- fasting insulin)/(30-minute glucose -- fasting glucose) ([@B34]) and DI~o~ (mg/dL)^--1^ = InsIndex × 1/fasting insulin ([@B35]). The DI~o~ is a measure of insulin secretion adjusted for insulin sensitivity. The logged value of InsIndex and DI~o~ was used in the analysis and results were back-transformed. The year 1 change (*∆*) in InsIndex and log DI~o~ was calculated by subtracting the baseline InsIndex or DI~o~ from the year 1 value. These insulinogenic quantitative measures are negatively associated with diabetes hazard rate in the DPP ([@B35]).

Diabetes incidence was determined by a diagnostic fasting or 2-hour glucose after a 75-g oral glucose tolerance test that was confirmed by a second test (fasting plasma glucose ≥126 mg/dL or 2-hour post--oral glucose tolerance test glucose level ≥200 mg/dL) ([@B36]).

We examined the 224 SNPs with MAF ≥1% in at least one ethnic group for association with insulin secretion indices and diabetes incidence. We assumed an additive genetic model. All models were adjusted for self-reported ethnicity, age at randomization, sex, and treatment group, with additional adjustment for the respective baseline trait for the association tests examining *Δ* log InsIndex and *Δ* log DI~o~. To examine how the SNP's effect is influenced by treatment group, the analysis was stratified by treatment group if the treatment group × SNP interaction was significant (*P* \< 0.05). We used an analysis of covariance and proportional hazards model to examine the association between the individual SNPs and insulinogenic traits and diabetes incidence, respectively. For the SNPs that were significantly associated with an insulinogenic trait, we performed an additional analysis using the SNP as a class variable (in two degrees-of-freedom tests), obtaining marginal means of the calculated insulin secretion indices and comparing differences between genotypic groups. Holm procedure was used to adjust *P* values when testing for differences between treatment groups when the interaction *P* value was significant for the year 1 change traits.

We examined the association of 224 common SNPs in a prior study ([@B27]) with diabetes incidence and reported that rs11868513 (*HNF1B*) and rs11086926 (*HNF4A*) were associated with diabetes incidence. To comprehensively examine the association of MODY variants and diabetes and related traits, in this report, we delved deeper into understanding these associations with diabetes incidence, as this was not investigated more closely in the prior study. In this study, we examined diabetes incidence by genotype per treatment group. We compared diabetes incidence for each genotype between the treatment groups using a *χ*^2^ test and corrected for multiple testing using stepdown Bonferroni correction.

Three methods were used to examine 19 rare missense SNPs in aggregate with each outcome. First, a genotype risk score (GRS) was calculated by assigning one point per minor allele. In a second examination, we used the combined multivariate and collapsing (CMC) method ([@B37]), which coded each participant having at least one allele with an MAF \<1% as "present" or no minor alleles "absent." A third technique used the sequence kernel association test (SKAT), which uses a multiple regression model and allows the variants to have different directions and magnitude of effects ([@B38]). SKAT was used only for testing associations with the insulinogenic traits because we were unable to incorporate the time variable into the analysis to assess diabetes incidence.

Additionally, we tested a "damaging" missense variants risk score for association with diabetes incidence composed of p.Val33Ala (C, *GCK*), p.Pro197His (rs8192556, A, *NEUROD1*), p.Leu176Ser (C, *NEUROD1*), p.His314Leu (T, *NEUROD1*), and p.Ser547Phe (T, *HNF1B*), which were determined to be probably damaging via bioinformatic analysis.

We chose to highlight SNPs that fulfilled a stringent study-wide significance level of *P* = 3 × 10^--4^ as determined by employing a Bonferroni correction for the estimated number of independent tests after taking linkage disequilibrium into account for 224 SNPs ([@B39], [@B40]) based on the HapMap sample's linkage disequilibrium structure in populations of European, African, and Asian ancestry (CEU, YRI, and CHP/JPT, respectively).

We compiled a list of variants in MODY-related variants from the literature that had been associated with diabetes in prior studies and examined them for association in the DPP with diabetes incidence. Additionally, we reviewed the published literature (88 publications) through December 2014 for prior reports of associations with diabetes and related traits for the missense variants identified in this study.

Results {#s9}
=======

Twenty-two missense variants were examined in this study, of which eight are unique. Three of the missense SNPs were common (overall MAF \>5%), whereas 19 had MAF \<5%. p.Val33Ala (*GCK*), p.Pro197His (rs8192556, *NEUROD1*), p.Leu176Ser (*NEUROD1*), p.His314Leu (*NEUROD1*), and p.Ser547Phe (*HNF1B*) were determined to be damaging to protein function consistently across two bioinformatics tools, PolyPhen-2 and SIFT ([Table 1](#T1){ref-type="table"}). The allele frequencies and number of individuals carrying each genotype by ethnicity for the 22 missense SNPs are provided in [Table 1](#T1){ref-type="table"} and Supplemental Table 1. A literature review of the missense SNPs for association with diabetes and related traits is in Supplemental Table 2.

###### 

**Bioinformatic Assessment of 22 Missense Variants**

  Residue Change and Codon Position                                                       Chromosome, Position (HG19)   MAF      Allele Change (Major to Minor)   rs Number     PolyPhen-2/SIFT
  --------------------------------------------------------------------------------------- ----------------------------- -------- -------------------------------- ------------- -----------------------------
  *GCK*                                                                                                                                                                         
   p.Ala11Thr                                                                             7, 44228522                   0.0027   [G]{.ul}CC-aCC                   rs116093166   Probably damaging/tolerated
   p.Thr396Ser[*^a^*](#t1n1){ref-type="table-fn"}                                         7, 44185162                   0.0006   A[C]{.ul}C-AgC                   N/A           Benign/damaging
   p.Glu272Ala[*^a^*](#t1n1){ref-type="table-fn"}                                         7, 44187297                   0.0003   G[A]{.ul}G-GcG                   N/A           Possibly damaging/tolerated
   p.Val33Ala[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}    7, 44193010                   0.0002   G[T]{.ul}G-GcG                   N/A           Possibly damaging/damaging
  *HNF4A*                                                                                                                                                                       
   p.Thr139Ile                                                                            20, 43042364                  0.0239   A[C]{.ul}T-AtT                   rs1800961     Benign/tolerated
  *NEUROD1*                                                                                                                                                                     
   p.Thr45Ala[*^b^*](#t1n2){ref-type="table-fn"}                                          2, 182543455                  0.3237   [G]{.ul}CC-aCC                   rs1801262     Benign/tolerated
   p.Pro197His[*^b^*](#t1n2){ref-type="table-fn"}                                         2, 182542998                  0.0185   C[C]{.ul}T-CaT                   rs8192556     Possibly damaging/damaging
   p.Val239Ile[*^b^*](#t1n2){ref-type="table-fn"}                                         2, 182542873                  0.0003   [G]{.ul}TC-aTC                   rs145050582   Benign/tolerated
   p.Leu176Ser[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}   2, 182543061                  0.0002   T[T]{.ul}A-TcA                   N/A           Possibly damaging/damaging
   p.His314Leu[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}   2, 182542647                  0.0006   C[A]{.ul}C-CtC                   N/A           Possibly damaging/damaging
  *HNF1A*                                                                                                                                                                       
   p.Ser487Asn[*^b^*](#t1n2){ref-type="table-fn"}                                         12, 121435427                 0.2993   A[G]{.ul}C-AaC                   rs2464196     Benign/tolerated
   p.Ala98Val[*^b^*](#t1n2){ref-type="table-fn"}                                          12, 121416864                 0.0239   G[C]{.ul}C-GtC                   rs1800574     Benign/tolerated
   p.Gly574Ser[*^b^*](#t1n2){ref-type="table-fn"}                                         12, 121437382                 0.0081   [G]{.ul}GC-aGC                   rs1169305     Benign/tolerated
   p.Arg583Gln[*^b^*](#t1n2){ref-type="table-fn"}                                         12, 121437410                 0.0009   C[G]{.ul}G-CaG                   rs137853242   Benign/tolerated
   p.Pro894Ser[*^b^*](#t1n2){ref-type="table-fn"}                                         12, 121432124                 0.0003   [C]{.ul}CA-tCA                   rs151256267   Benign/tolerated
   p.Ile27Leu[*^b^*](#t1n2){ref-type="table-fn"}                                          12, 121416650                 0.2927   [A]{.ul}TC-cTC                   rs1169288     Benign/tolerated
   p.Gly554Arg                                                                            12, 121437322                 0.0005   [G]{.ul}GG-aGG                   N/A           Probably damaging/tolerated
  *HNF1B*                                                                                                                                                                       
   p.Gly370Ser[*^b^*](#t1n2){ref-type="table-fn"}                                         17, 36070609                  0.0009   [G]{.ul}GC-aGC                   rs113042313   Benign/tolerated
   p.Asn228Lys                                                                            17, 33363607                  0.0042   AA[C]{.ul}-AAg                   N/A           Benign/damaging
   p.Ser547Phe[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}   17, 36059095                  0.0002   T[C]{.ul}T-TtT                   N/A           Probably damaging/damaging
   p.Thr436Ser[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}   17, 36064957                  0.0002   [A]{.ul}CA-tCA                   N/A           Benign/tolerated
   p.His332Gln[*^a^*](#t1n1){ref-type="table-fn"}                                         17, 36091635                  0.0005   CA[C]{.ul}-CAg                   N/A           Probably damaging/tolerated

Major allele denoted by underline. We used the publicly available assessment tools PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2>) and SIFT (<http://sift.jcvi.org>) to predict if amino acid changes could be detrimental to protein function ([@B29][@B30]--[@B31]). PolyPhen-2 predictions were based on the Hum Div testing model. This model was compiled from all damaging alleles with known effects on the molecular function causing human Mendelian diseases, present in the UniProtKB database, together with differences between human proteins and their closely related mammalian homologs, assumed to be nondamaging.

Abbreviation: N/A, not available.

Indicates a unique variant.

SNPs were consistent for both bioinformatics tools.

Individual variants and aggregate scores tested for association with baseline insulin secretion traits are shown in [Table 2](#T2){ref-type="table"} and Supplemental Table 3.

###### 

**MODY SNPs Associated With Log Baseline InsIndex at *P* \< 3 × 10^--4^ and Their Association With Log Baseline DI~o~ and Insulin Sensitivity (Log 1/FI)**

  Gene        SNP                    Alleles (Effect/Other)     Log Baseline InsIndex   Log Baseline DI~o~   Log Baseline 1/FI   Diabetes Incidence                                                                            
  ----------- ---------------------- -------------------------- ----------------------- -------------------- ------------------- ---------------------- ---------------- ------- ------------------ ------ ------------------- ------
  *NEUROD1*   rs11884960             [A]{.ul}/G (MAF = 2.2%)    0.084 (0.023)           3 × 10^--4^          GG (3291)           1.200 (1.149--1.252)   0.065 (0.034)    0.06    --0.065 (0.044)    0.14   0.71 (0.48--1.07)   0.10
  AG (135)    1.502 (1.332--1.681)                                                                                                                                                                                             
  AA (9)      1.501 (0.940--2.177)                                                                                                                                                                                             
  *PDX1*      rs4769581              [T]{.ul}/C (MAF = 39%)     0.027 (0.007)           2 × 10^--4^          CC (1267)           1.149 (1.086--1.213)   0.026 (0.0105)   0.01    --0.005 (0.0134)   0.71   1.0 (0.88--1.13)    1.0
  TC (1666)   1.223 (1.164--1.283)                                                                                                                                                                                             
  TT (506)    1.317 (1.230--1.407)                                                                                                                                                                                             
  *HNF1B*     rs3110638              [A]{.ul}/G (MAF = 0.83%)   0.145 (0.038)           1 × 10^--4^          GG (3376)           1.933 (0.342--4.689)   0.182 (0.0557)   0.001   0.034 (0.0716)     0.64   0.86 (0.45--1.6)    0.64
  AG (55)     1.691 (1.426--1.977)                                                                                                                                                                                             
  AA (1)      1.207 (1.156--1.259)                                                                                                                                                                                             

The underlined alleles designate the minor allele. The adjusted means are back-transformed for InsIndex. Supplemental Table 3 shows the association of all the SNPs examined and baseline insulinogenic traits.

Abbreviations: FI, fasting insulin; HR, hazard ratio; *β* (SE), *β* estimate (standard error) of the association of each minor allele with the respective trait.

Two SNPs were found to have a significant SNP × treatment interaction and, after stratifying by treatment group, reached the study-wide level of significance for association with *Δ* log DI~o~ in either the lifestyle or metformin groups. SNP rs3212185 (*HNF4A*), which was predominant in African-American participants (MAF 0.08), had an SNP × lifestyle *vs* placebo *P*~interaction~ = 0.0002. The C allele (minor) of rs3212185 was associated with an increase in log DI~o~ in response to the lifestyle intervention over 1 year that was absent in the placebo group and attenuated in the metformin group. A consistent relationship was noted for association with *Δ* log InsIndex, though at a weaker level of statistical significance ([Table 3](#T3){ref-type="table"}). Heterozygotes at rs3212185 had an increase in mean DI~o~ from baseline (0.0481, 95% confidence interval \[CI\]: 0.031 to 0.065) to 1 year (0.117, 95% CI: 0.094 to 0.141) in the lifestyle group, compared with heterozygotes in the placebo group and TT homozygotes in the placebo and lifestyle groups, where DI~o~ remained unchanged \[[Fig. 1(a)](#F1){ref-type="fig"}\].

###### 

**Genetic Variation in *HNF4A* and *NEUROD1* Influences the Improvement in Insulin Secretion in One of the Treatment Groups**

  Gene                                                          SNP         Trait              Alleles                   SNP × Treatment Interaction   Placebo           Metformin   Lifestyle                                       
  ------------------------------------------------------------- ----------- ------------------ ------------------------- ----------------------------- ----------------- ----------- --------------- ------------- ----------------- -------------
  *HNF4A*                                                                                                                                                                                                                            
   Significant interaction for SNP × lifestyle (*vs* placebo)                                                                                                                                                                        
                                                                rs3212185   *Δ* log InsIndex   [C]{.ul}/T (MAF = 1.7%)   0.01                          --0.005 (0.200)   0.98        0.493 (0.167)   0.003         0.396 (0.173)     0.02
                                                                            *Δ* log DI~o~                                0.0002                        --0.001 (0.008)   0.88        0.017 (0.007)   0.03          0.043 (0.011)     2 × 10^--4^
  *NEUROD1*                                                                                                                                                                                                                          
   Significant interaction for SNP × metformin (*vs* placebo)                                                                                                                                                                        
                                                                rs6719578   *Δ* log InsIndex   [C/]{.ul}G (MAF = 1.2%)   0.03                          0.028 (0.233)     0.90        0.525 (0.229)   0.02          --0.092 (0.210)   0.66
                                                                            *Δ*log DI~o~                                 0.002                         --0.003 (0.010)   0.79        0.042 (0.010)   1 × 10^--4^   0.005 (0.014)     0.72

The underlined allele is the minor allele.

Abbreviation: *β* (SE), *β* estimate (standard error) of the association of each minor allele with the respective trait.

![SNPs in *HNF4A* and *NEUROD1* were associated with a significant SNP × treatment interaction and insulin secretion as measured by DI~o~. This figure displays the adjusted means at baseline and year 1 of these SNPs comparing the two groups that demonstrated the interaction. The minor homozygotes are not shown because, due to low frequency, they were not present in all of the treatment groups. (a) rs3212185 × lifestyle (*vs* placebo) interaction, *P* value = 0.0002. TC heterozygotes (gray circle and dotted line) at SNP rs3212185 showed improved DI~o~ after 1 year of lifestyle intervention, whereas the TT (gray circle and solid line) homozygotes had no response to lifestyle intervention. The TT and TC genotypes in the placebo group (black square) did not change in DI~o~. (b) rs6719578 × metformin (*vs* placebo) interaction, *P* value = 0.002. GC heterozygotes (gray triangle and dotted line) at SNP rs6719578 had improved DI~o~ after 1 year of metformin intervention, whereas the GG (gray triangle and solid line) homozygotes did not respond to metformin intervention. Participants with the GG and GC (black square) genotypes in the placebo group did not change DI~o~.](jc.2016-3429f1){#F1}

SNP rs6719578 (*NEUROD1*) had an SNP × metformin *vs* placebo *P*~interaction~ = 0.002. The C allele (minor) of rs6719578 was associated with a positive *Δ* log DI~o~ among the metformin-treated participants during the first year that was not seen in the placebo or lifestyle groups. The C allele was similarly associated with *Δ* log InsIndex among the metformin group at a lower level of statistical significance (*P* = 0.02). Heterozygotes had an increase in mean DI~o~ from baseline (0.057, 95% CI: 0.041 to 0.072) to 1 year (0.086, 95% CI: 0.07 to 0.10) in the metformin group, whereas DI~o~ in heterozygotes in the placebo group and in GG homozygotes in the placebo and metformin groups remained largely flat, if not trending downward \[[Fig. 1(b)](#F1){ref-type="fig"}\].

All the individual variants and aggregate scores tested for association with *Δ* log InsIndex and *Δ* log DI~o~ are shown in Supplemental Tables 4 and 5.

None of the common missense variants nor the GRS and CMC scores of the 19 rare missense variants were associated with change in the insulinogenic traits over the first year. The SKAT analysis revealed a nominally significant association between the aggregate of the 19 uncommon missense variants and change in InsIndex (*P* = 0.03) but no change in DI~o~ (*P* = 0.6) (Supplemental Table 6).

We have shown previously that SNPs rs11086926 (*HNF4A*) and rs11868513 (*HNF1B*) were associated with diabetes incidence in one of the treatment groups ([@B27]), with significant genotype × treatment interactions. To investigate this further, we examined diabetes incidence by genotype within each treatment group ([Fig. 2](#F2){ref-type="fig"}). GG homozygotes at rs11086926 in the lifestyle group were less likely to develop diabetes compared with persons with the same genotype in the placebo (*P =* 0.02) and metformin (*P =* 0.02) groups, with no difference between the metformin and placebo groups \[[Fig. 2(a)](#F2){ref-type="fig"}\]. AA homozygotes at rs11868513 had the highest diabetes incidence in the placebo group but a dramatic response to metformin (*P* = 0.008) and lifestyle (*P* = 0.002) therapy. AG heterozygotes had lower diabetes incidence rates than AA homozygotes, but their rates were also lowered both by lifestyle (*P* \< 0.001) and metformin (*P* = 0.002). Diabetes incidence rates were lowered in GG homozygotes by the lifestyle intervention (*P* \< 0.001) but not significantly by metformin (*P* = 0.2) compared with placebo \[[Fig. 2(b)](#F2){ref-type="fig"}\].

![Diabetes diagnoses per 100 patient-years for (a) rs11086926 and (b) rs11868513 for each genotype group within each treatment arm. (a) The GG homozygotes of rs11086926 had a differential response to lifestyle and metformin (rs11086926 × metformin *vs* placebo, *P*~interaction~ = 0.002). The GG carriers in the lifestyle group had a significantly lower diabetes incidence than did carriers of the same genotype in the placebo (*P =* 0.007) and metformin (*P =* 0.006) groups. These GG homozygotes had no response to metformin therapy compared with placebo (*P =* 0.8). (b) There was a significant treatment × genotype interaction for rs1186513. rs11868513 × metformin *vs* placeb, *P*~interaction~ = 0.0007, and rs11868513 × lifestyle *vs* placebo *P*~interaction~ = 0.03. The AA genotype of rs11868513, despite having a higher diabetes risk in the placebo group, had a dramatic response to metformin (*P* = 0.008) and lifestyle (*P* = 0.001) therapy. The AG genotype also demonstrated a decrease to both lifestyle (*P* \< 0.001) and metformin (*P* = 0.002) therapy compared with placebo. The GG genotype carriers showed a decrease in diabetes incidence to lifestyle intervention (*P* \< 0.001) and no response to metformin (*P* = 0.2) compared with placebo.](jc.2016-3429f2){#F2}

Neither the missense variant GRS nor CMC burden scores were associated with diabetes incidence. Association results for diabetes incidence in the DPP for variants in MODY genes previously associated with type 2 diabetes are shown in [Table 4](#T4){ref-type="table"}.

###### 

**Replication of Previously Reported Type 2 Diabetes--Associated MODY Genetic Variants for Association With Diabetes Incidence in the DPP**

  SNP                                                     Effect/Other   Gene        OR[*^a^*](#t4n1){ref-type="table-fn"} (95% CI)         Proxy (Effect/Other)[*^b^*](#t4n2){ref-type="table-fn"}   *r*^2^ (CEU)   Diabetes HR (95% CI)   *P* Value
  ------------------------------------------------------- -------------- ----------- ------------------------------------------------------ --------------------------------------------------------- -------------- ---------------------- -----------
  rs2244164 ([@B9])                                       C/T            *GCK*       0.81 (0.72--0.92)                                      rs2080033 (C/T)                                           1              1.05 (0.93--1.18)      0.42
  rs1169288 ([@B11])                                      T/G            *HNF1A*     1.20 (1.10--1.3)[*^a^*](#t4n1){ref-type="table-fn"}                                                                             0.99 (0.87--1.12)      0.89
  rs2701175 ([@B9])                                       C/A            *HNF1A*     1.34 (1.06--1.68)                                      rs1169288 (G/T)                                           0.6            1.01 (0.89--1.15)      0.89
  rs2071190 ([@B9])                                       A/T            *HNF1A*     2.08 (1.30--3.31)                                                                                                               1.10 (0.96--1.27)      0.15
  rs7305618[*^a^*](#t4n1){ref-type="table-fn"} ([@B18])   C/T            *HNF1A*     1.14 (1.09--1.20)                                                                                                               0.98 (0.86--1.12)      0.80
  rs7957197[*^a^*](#t4n1){ref-type="table-fn"} ([@B17])   T/A            *HNF1A*     1.07 (1.05--1.10)                                      rs7305618 (G/A)                                           0.57           0.98 (0.86--1.12)      0.80
  rs11263755 ([@B10])                                     A/G            *HNF1B*     1.13 (1.04--1.23)                                                                                                               0.92 (0.79--1.05)      0.22
  rs2285741 ([@B10])                                      A/G            *HNF1B*     0.94 (0.88--1.00)                                                                                                               0.89 (0.79--1.01)      0.06
  rs2689 ([@B10])                                         A/T            *HNF1B*     1.09 (1.02--1.17)                                                                                                               1.08 (0.96--1.22)      0.19
  rs3110641 ([@B10])                                      C/T            *HNF1B*     1.10 (1.04--1.17)                                                                                                               0.96 (0.85--1.1)       0.57
  rs3094513 ([@B10])                                      T/C            *HNF1B*     1.08 (1.01--1.16)                                      rs3110640 (C/T)                                           0.93           1.09 (0.97--1.23)      0.14
  rs757210 ([@B10])                                       A/G            *HNF1B*     1.12 (1.07--1.18)                                                                                                               1.13 (1.01--1.27)      0.04
  rs12450628 ([@B9])                                      T/C            *HNF1B*     1.63 (1.20--2.23)                                      rs2411153 (C/G)                                           0.68           0.89 (0.80--1.00)      0.06
  rs1008284 ([@B9])                                       A/G            *HNF1B*     0.53 (0.37--0.75)                                                                                                               1.07 (0.94--1.22)      0.32
  rs4430796[*^a^*](#t4n1){ref-type="table-fn"} ([@B17])   G/A            *HNF1B*     1.14 (1.08--1.20)                                                                                                               1.08 (0.96--1.21)      0.17
  rs4810424 ([@B11])                                      C /G           *HNF4A*     1.30 (1.00--1.60)[*^c^*](#t4n3){ref-type="table-fn"}   rs1884614 (A/G)                                           0.95           1.04 (0.90--1.20)      0.58
  rs3212198 ([@B11])                                      C/T            *HNF4A*     1.10 (1.00--1.20)[*^c^*](#t4n3){ref-type="table-fn"}                                                                            0.96 (0.86--1.08)      0.54
  rs6103716 ([@B9])                                       C/A            *HNF4A*     1.26 (1.11--1.44)                                                                                                               1.07 (0.95--1.21)      0.25
  rs6017317[*^a^*](#t4n1){ref-type="table-fn"} ([@B20])   G/T            *HNF4A*     1.09 (1.07--1.12)                                      rs1884614 (A/G)                                           0.7            1.04 (0.90--1.20)      0.58
  rs4812829[*^a^*](#t4n1){ref-type="table-fn"} ([@B19])   A/G            *HNF4A*     1.09 (1.06--1.12)                                      rs1884614 (A/G)                                           1              1.04 (0.90--1.20)      0.58
  rs3916026 ([@B9])                                       C/G            *NEUROD1*   0.73 (0.61--0.87)                                                                                                               1.00 (0.88--1.12)      0.94
  rs2297316[*^d^*](#t4n4){ref-type="table-fn"} ([@B9])    A/G            *PDX1*      0.77 (0.64--0.92)                                                                                                               ---                    ---

The article origin for each SNP is in parentheses to the right of the SNP.

Abbreviations: HR, hazard ratio; OR, odds ratio.

SNPs found to be associated with type 2 diabetes in GWASs.

Proxy alleles are consistent with the major or minor effect allele in the original study.

The effect represents a hazard ratio.

rs2297316 did not have an adequate proxy (*r*^2^ \> 0.5) genotyped in the DPP.

Discussion {#s10}
==========

We have examined genetic variation among six canonical MODY genes for association with insulinogenic traits and diabetes incidence in response to diabetes preventive interventions. Our key findings show that genetic variation within *HNF4A*, *HNF1B*, and *NEUROD1* is associated with a differential response to lifestyle and/or metformin interventions in insulinogenic traits and diabetes development. Our study supports prior findings demonstrating that variation in genes where pathogenic mutations are known to cause MODY contribute to the risk of diabetes and variation in insulinogenic traits ([@B9][@B10]--[@B11], [@B17]--[@B20], [@B22]). We furthermore demonstrated how the influence of variation in MODY genes is modified by insulin-sensitizing interventions.

Among common variants in MODY genes previously associated with type 2 diabetes from candidate gene studies and GWASs (listed in [Table 4](#T4){ref-type="table"}), we replicated rs757210 in *HNF1B* for association with diabetes incidence ([@B10]). We reported an association between rs11868513 in *HNF1B* and diabetes incidence among the placebo group participants, but rs11868513 and rs757210 are not in linkage disequilibrium (*r*^2^ \< 0.009) and appear to be exerting independent effects on diabetes incidence.

In a comprehensive literature review of the missense variants identified among the DPP participants (summarized in Supplemental Table 2), we illustrate how these variants have been associated with diabetes and related traits in prior literature. Three low-frequency variants \[p.Thr45Ala (*NEUROD1*), p.Ser487Asn (*HNF1A*), and p.Ile27Leu (*HNF1A*)\] have been studied most comprehensively previously. p.Thr45Ala (rs1801262) has been associated with *β*-cell dysfunction in both type 1 and type 2 diabetes ([@B41], [@B42]) and a faster deterioration in *β*-cell function ([@B43]) in Asians. The DPP may be underpowered to detect this association in participants with Asian ancestry. We confirmed findings for association of Ser487Asn (rs2464196) with baseline DI~o~ (*P* = 0.02) ([@B11], [@B44]), although this finding was not seen in other reports where a variety of tools were used to measure *β*-cell function ([@B45][@B46]--[@B47]). Last, we confirmed prior findings of the association of Ile27Leu (rs1169288) with *β*-cell function (InsIndex, *P* = 0.006) ([@B11], [@B44], [@B48]).

In contrast to prior case-control, cross-sectional, or observational prospective studies, the DPP randomized design allowed us to characterize how these genetic variants might influence response to diabetes preventive interventions. Because DPP participants were phenotyped at regular intervals for glycemia-related traits during the study intervention, we were able to assess *β*-cell function during the first year in response to treatment. This is of particular relevance to MODY genes, as the primary defect in the monogenic disease is impaired insulin secretion ([@B1]). Two SNPs (rs3212185 \[*HNF4A*\] and rs671978 \[*NEUROD1*\]) showed significant interactions with the lifestyle or metformin interventions, respectively, and reached study-wide statistical significance for association with change in insulin secretion after stratification in one of the treatment groups. At both SNPs, heterozygote minor allele carriers showed an improvement in insulin secretion as measured by DI~o~ during the first year compared with the major allele homozygotes, an effect that was not seen in the placebo arm.

SNP rs3212185 (*HNF4A*) and rs671978 (*NEUROD1*) are in genes that are crucial to *β*-cell function. *HNF4A* and *NEUROD1* are transcription factors that are involved in endocrine pancreatic development and regulate insulin gene transcription ([@B1]). Insulin sensitivity is known to modulate insulin secretion. In the DPP, the lifestyle intervention improved insulin sensitivity and enhanced *β*-cell function ([@B35]). The metformin intervention had a similar attenuated result. We have shown that genetic variation in *HNF4A* and *NEUROD1* modifies the response to interventions designed to improve insulin resistance \[metformin and lifestyle (diet, exercise, and weight loss)\]. The major homozygotes at rs3212185 and rs671978 appear resistant to improvement in *β*-cell function by lifestyle and metformin therapy, respectively, whereas minor allele carriers have enhanced *β*-cell function ([@B1]). These findings underscore that interventions that improve insulin resistance may contribute to improvement in *β*-cell function among certain genotype carriers in genes known to impair insulin secretion. It is notable that rs3212185 is associated with glycemic traits among predominantly African ancestry carriers, where *HNF4A* variation has not been studied in detail despite the higher type 2 diabetes risk in this population ([@B49]).

SNP rs11086926 showed a significant interaction with metformin on diabetes incidence ([@B27]). Specifically, minor allele homozygotes at rs11086926 appear to be resistant to metformin therapy but were responsive to lifestyle intervention. Perhaps the minor allele carriers are resistant to metformin's action in decreasing insulin resistance at the liver, where *HNF4A* is also highly expressed ([@B49]). This variant has been shown to be nominally associated with type 2 diabetes in GWASs of Hispanic ancestry ([@B50]).

SNP rs11868513 showed a significant interaction with metformin and lifestyle interventions ([@B27]). The metformin and lifestyle interventions ablated the increased diabetes risk seen among the A allele carriers in the placebo group. Furthermore, AA carriers had a substantial decrease in diabetes incidence with metformin therapy and lifestyle intervention. These results illustrate that metformin and lifestyle interventions reduce the risk of diabetes of AA carriers to the levels of GG and AG carriers.

We used three methods to investigate the contribution of an aggregate of 19 rare missense variants on diabetes incidence and insulinogenic traits. Similar to the study by Flannick *et al.* ([@B12]) in an unselected population, MODY missense variants did not appear to influence diabetes incidence in our high-risk population. Using SKAT, a method that does not assume that rare variants influence the phenotype in the same direction, we found a nominally significant association between the aggregate of 19 missense variant's baseline InsIndex and DI~o~ and the *Δ* InsIndex over the first year. Because SKAT provides a *P* value but no effect estimate, we would need to test each variant individually to determine which SNP(s) may be driving the association and the direction of effect. We are not powered to test these rare variants individually in the DPP but, using publically available databases for type 2 diabetes, we noted that p.Val33Ala (*GCK*), p.Thr139Ile (*HNF4A*), p.Ala98Val (*HNF1A*), and p.Ile27Leu (*HNF1A*) have been associated with type 2 diabetes at nominal to locus-wide levels of significance ([@B50]), which supports the suggested association with the aggregate of missense variants and insulinogenic traits. Nonetheless, large cohorts genotyped for the missense variants examined here will have the power to further explore the individual contribution of rare missense variants in the MODY genes on diabetes incidence and insulinogenic traits.

Some limitations of our study should be emphasized. First, as our sequencing efforts started prior to the introduction of next-generation sequencing techniques, we only sequenced six MODY genes in 190 participants and so did not comprehensively catalog all rare variation in our sample of 3442 individuals. Second, because sample sizes in clinical trials are finite, power to detect associations with rare variants is limited. Third, we have not examined newly discovered MODY genes. Fourth, we have not been able to replicate our results, as suitable venues to do so are not available for this unique clinical trial; thus, though we have tried to be circumspect in the selection of statistical thresholds, the findings reported here should be considered hypothesis generating. Some of these limitations will be overcome with the deployment of an exome array in the DPP, which will allow for a more thorough evaluation of low-frequency variants across all MODY genes.

In summary, select MODY gene variants annotated to *HNF4A*, *HNF1B*, and *NEUROD1* are associated with response to insulin-sensitizing interventions on either diabetes incidence and/or insulinogenic traits. These results provide evidence that genetic variation among MODY genes influences response to insulin-sensitizing interventions. These data underscore the need for further genotype-directed studies to determine whether carriers of the aforementioned gene variants respond differently to insulin-sensitizing and, moreover, insulin secretagogue therapy.

Abbreviations: CIconfidence intervalCMCcombined multivariate and collapsingDI~o~oral disposition indexDPPDiabetes Prevention ProgramGRSgenotype risk scoreGWASgenome-wide association studyInsIndexinsulinogenic indexMAFminor allele frequencyMODYmaturity-onset diabetes of the youngSKATsequence kernel association testSNPsingle-nucleotide polymorphism.
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